Costs and clinical consequences of suboptimal atrial fibrillation management

References

• BajpaiASavelievaICammAJEpidemiology and economic burden of atrial fibrillationTouch Briefings20071417
   Google Scholar
• DorianPMangatIPinterAKorleyVThe burden of atrial fibrillation: should we abandon antiarrhythmic drug therapy?J Cardiovasc Pharmacol Ther20049425726215678244
   PubMed Web of Science ®Google Scholar
• NaccarelliGVVarkerHLinJSchulmanKLIncreasing prevalence of atrial fibrillation and flutter in the United StatesAm J Cardiol2009104111534153919932788
   PubMed Web of Science ®Google Scholar
• WattigneyWAMensahGACroftJBIncreasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary preventionCirculation2003108671171612885749
   PubMed Web of Science ®Google Scholar
• BialyDHospitalization for arrhythmias in the United States: Importance of atrial fibrillation [abstract 716–714]J Am Coll Cardiol199219341A
   Google Scholar
• WyseDGGershBJAtrial fibrillation: a perspective: thinking inside and outside the boxCirculation2004109253089309515226225
   PubMed Web of Science ®Google Scholar
• ChatapGGiraudKVincentJPAtrial fibrillation in the elderly: facts and managementDrugs Aging2002191181984612428993
   PubMed Web of Science ®Google Scholar
• HagensVERanchorAVVan SonderenEEffect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) StudyJ Am Coll Cardiol200443224124714736444
   PubMed Web of Science ®Google Scholar
• DorianPJungWNewmanDThe impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapyJ Am Coll Cardiol20003641303130911028487
   PubMed Web of Science ®Google Scholar
• PaquetteMRoyDTalajicMRole of gender and personality on quality-of-life impairment in intermittent atrial fibrillationAm J Cardiol200086776476811018197
   PubMed Web of Science ®Google Scholar
• KannelWBAbbottRDSavageDDMcNamaraPMEpidemiologic features of chronic atrial fibrillation: the Framingham studyN Engl J Med198230617101810227062992
   PubMed Web of Science ®Google Scholar
• WattigneyWAMensahGACroftJBIncreased atrial fibrillation mortality: United States, 1980–1998Am J Epidemiol2002155981982611978585
   PubMed Web of Science ®Google Scholar
• Atrial fibrillation as a contributing cause of death and Medicare hospitalization – United States, 1999MMWR Morb Mortal Wkly Rep200352712813012813112617537
   PubMedGoogle Scholar
• SinghSNTangXCSinghBNQuality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program SubstudyJ Am Coll Cardiol200648472173016904540
   PubMed Web of Science ®Google Scholar
• CoyneKSParamoreCGrandySMercaderMReynoldsMZimetbaumPAssessing the direct costs of treating nonvalvular atrial fibrillation in the United StatesValue Health20069534835616961553
   PubMed Web of Science ®Google Scholar
• WuEQBirnbaumHGMarevaMEconomic burden and co-morbidities of atrial fibrillation in a privately insured populationCurr Med Res Opin200521101693169916238910
   PubMed Web of Science ®Google Scholar
• LeeWCLamasGABaluSSpaldingJWangQPashosCLDirect treatment cost of atrial fibrillation in the elderly American population: a Medicare perspectiveJ Med Econ200811228129819450086
   PubMedGoogle Scholar
• AnisRRRole of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillationExp Clin Cardiol2009141e1e719492029
   PubMedGoogle Scholar
• FusterVRydenLECannomDS2011ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyJ Am Coll Cardiol20115711e101e19821392637
   PubMed Web of Science ®Google Scholar
• TengMPCatherwoodLEMelbyDPCost effectiveness of therapies for atrial fibrillation. A reviewPharmacoeconomics200018431733315344302
   PubMed Web of Science ®Google Scholar
• WyseDGWaldoALDiMarcoJPA comparison of rate control and rhythm control in patients with atrial fibrillationN Engl J Med2002347231825183312466506
   PubMed Web of Science ®Google Scholar
• BushnellCDMatcharDBPharmacoeconomics of atrial fibrillation and stroke preventionAm J Manag Care200410Suppl 3S66S7115152748
   PubMedGoogle Scholar
• GageBFWatermanADShannonWBoechlerMRichMWRadfordMJValidation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial FibrillationJAMA2001285222864287011401607
   PubMed Web of Science ®Google Scholar
• IshakKJProskorovskyIGuoSLinJPersistence with antiarrhythmics and the impact on atrial fibrillation-related outcomesAm J Pharm Benefits200914193200
   Google Scholar
• NaccarelliGVDell’OrfanoJTWolbretteDLPatelHMLuckJCCost-effective management of acute atrial fibrillation: role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapyAm J Cardiol20008510A36D45D
   Web of Science ®Google Scholar
• KimMHJohnstonSSChuBCDalalMRSchulmanKLEstimation of total incremental health care costs in patients with atrial fibrillation in the United StatesCirc Cardiovasc Qual Outcomes20114331332021540439
   PubMed Web of Science ®Google Scholar
• KimMHLinJHusseinMBattlemanDIncidence and temporal pattern of hospital readmissions for patients with atrial fibrillationCurr Med Res Opin20092551215122019327101
   PubMed Web of Science ®Google Scholar
• KimMHLinJHusseinMKreilickCBattlemanDCost of atrial fibrillation in United States managed care organizationsAdv Ther200926911119129998
   PubMed Web of Science ®Google Scholar
• PatelPPJohnstonSJLinJSchulmanKLNaccarelliGVCost burden of hospitalization and mortality in United States atrial fibrillation/flutter patients [abstract PO03-53]Presented at: Heart Rhythm 2009May 13–16, 2009Boston, MA
   Google Scholar
• KimMHKlingmanDLinJBattlemanDSPatterns and predictors of discontinuation of rhythm-control drug therapy in patients with newly diagnosed atrial fibrillationPharmacotherapy200929121417142619947801
   PubMed Web of Science ®Google Scholar
• KimMHKlingmanDLinJPathakPBattlemanDSCost of hospital admission for antiarrhythmic drug initiation in atrial fibrillationAnn Pharmacother200943584084819417111
   PubMed Web of Science ®Google Scholar
• Berlex LaboratoriesBetapace [package insert]Wayne, NJBerlex Laboratories, Inc2010
   Google Scholar
• PfizerTikosyn [package insert]New York, NYPfizer Labs2006
   Google Scholar
• KimMHLinJHusseinMBattlemanDIncidence and economic burden of suspected adverse events and adverse event monitoring during AF therapyCurr Med Res Opin200925123037304719852699
   PubMed Web of Science ®Google Scholar
• World Health OrganizationShaping the Future The World Health Report 2003Geneva, SwitzerlandWorld Health Organization20031204
   Google Scholar
• WolfPAAbbottRDKannelWBAtrial fibrillation as an independent risk factor for stroke: the Framingham StudyStroke19912289839881866765
   PubMed Web of Science ®Google Scholar
• The Atrial Fibrillation InvestigatorsRisk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trialsArch Intern Med199415413144914578018000
   PubMedGoogle Scholar
• SzucsTDBramkampMPharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a reviewJ Thromb Haemost2006461180118516706956
   PubMed Web of Science ®Google Scholar
• RyderKMBenjaminEJEpidemiology and significance of atrial fibrillationAm J Cardiol1999849A131R138R
   Web of Science ®Google Scholar
• MillerPSAnderssonFLKalraLAre cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?Stroke200536236036615637326
   PubMed Web of Science ®Google Scholar
• DulliDAStankoHLevineRLAtrial fibrillation is associated with severe acute ischemic strokeNeuroepidemiology200322211812312629277
   PubMed Web of Science ®Google Scholar
• BoccuzziSJMartinJStephensonJRetrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleedCurr Med Res Opin200925122853286419916729
   PubMed Web of Science ®Google Scholar
• CaroJJAn economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulationAm J Manag Care200410Suppl 14S451S45815696909
   PubMed Web of Science ®Google Scholar
• EzekowitzMDFalkRHThe increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillationMayo Clin Proc200479790491315244388
   PubMed Web of Science ®Google Scholar
• WittkowskyAKEffective anticoagulation therapy: defining the gap between clinical studies and clinical practiceAm J Manag Care200410Suppl 10S297S30615605700
   PubMed Web of Science ®Google Scholar
• ThosaniAJXiongYLinJKothawalaPZimetbaumPJAre atrial fibrillation patients receiving anticoagulation in accordance with their stroke risk? [abstract PO06-60]Presented at: Heart Rhythm 2009May 13–16, 2009Boston, MA
   Google Scholar
• DamaskeDLBairdRWDevelopment and implementation of a pharmacist-managed inpatient warfarin protocolProc (Bayl Univ Med Cent)200518439740016252031
   PubMedGoogle Scholar
• NYSED.govPractice Alerts and Guidelines: Coumadin (Warfarin) Managed Dosing by NursesJune 252009New York State Education Department Office of the Professions Available from: http://www.op.nysed.gov/prof/nurse/nurse-coumadin.htmAccessed December 12, 2011
   Google Scholar
• ChiquetteEAmatoMGBusseyHIComparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costsArch Intern Med199815815164116479701098
   PubMed Web of Science ®Google Scholar
• ScottPAPancioliAMDavisLAFrederiksenSMEckmanJPrevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patientsStroke200233112664266912411658
   PubMed Web of Science ®Google Scholar
• McCormickDGurwitzJHGoldbergRJPrevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care settingArch Intern Med2001161202458246311700158
   PubMedGoogle Scholar
• SamsaGPMatcharDBGoldsteinLBQuality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communitiesArch Intern Med2000160796797310761962
   PubMed Web of Science ®Google Scholar
• SorensenSVDewildeSSingerDEGoldhaberSZMonzBUPlumbJMCost-effectiveness of warfarin: trial versus “real-world” stroke prevention in atrial fibrillationAm Heart J200915761064107319464418
   PubMed Web of Science ®Google Scholar
• SingerDEAlbersGWDalenJEGoASHalperinJLManningWJAntithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyChest2004126Suppl 3429S456S15383480
   PubMed Web of Science ®Google Scholar
• AlbersGWDienerHCFrisonLXimelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trialJAMA2005293669069815701910
   PubMed Web of Science ®Google Scholar
• BoulangerLKimJFriedmanMHauchOFosterTMenzinJPatterns of use of antithrombotic therapy and quality of anticoagulation among patients with non-valvular atrial fibrillation in clinical practiceInt J Clin Pract200660325826416494639
   PubMed Web of Science ®Google Scholar
• SullivanPWArantTWEllisSLUlrichHThe cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the USPharmacoeconomics200624101021103317002484
   PubMed Web of Science ®Google Scholar
• GhateSRBiskupiakJYeXKwongWJBrixnerDIAll-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillationJ Manag Care Pharm201117967268422050392
   PubMed Web of Science ®Google Scholar
• BaetzBESpinlerSADabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseasesPharmacotherapy200828111354137318956996
   PubMed Web of Science ®Google Scholar
• FranchiniMMannucciPMA new era for anticoagulantsEur J Intern Med200920656256819782914
   PubMed Web of Science ®Google Scholar
• De CaterinaRKristensenSDRendaGNew anticoagulants for atrial fibrillationJ Cardiovasc Med (Hagerstown)200910644645319365276
   PubMed Web of Science ®Google Scholar
• SamamaMMGerotziafasGTNewer anticoagulants in 2009J Thromb Thrombolysis20102919210419838770
   PubMed Web of Science ®Google Scholar
• PatelMRMahaffeyKWGargJRivaroxaban versus warfarin in nonvalvular atrial fibrillationN Engl J Med20113651088389121830957
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm [press release]November 42011 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm278646.htmAccessed November 7, 2011
   Google Scholar
• ConnollySJEikelboomJJoynerCApixaban in patients with atrial fibrillationN Engl J Med2011364980681721309657
   PubMed Web of Science ®Google Scholar
• GrangerCBAlexanderJHMcMurrayJJApixaban versus warfarin in patients with atrial fibrillationN Engl J Med20113651198199221870978
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves Pradaxa to prevent stroke in people with atrial fibrillationOctober 192010 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241.htmAccessed July 13, 2011
   Google Scholar
• EzekowitzMDConnollySParekhARationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAm Heart J2009157580581019376304
   PubMed Web of Science ®Google Scholar
• ConnollySJEzekowitzMDYusufSDabigatran versus warfarin in patients with atrial fibrillationN Engl J Med2009361121139115119717844
   PubMed Web of Science ®Google Scholar
• WannLSCurtisABJanuaryCT2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation201112310412321173346
   PubMed Web of Science ®Google Scholar
• ReynoldsMREssebagVZimetbaumPCohenDJHealthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registryJ Cardiovasc Electrophysiol200718662863317451468
   PubMed Web of Science ®Google Scholar
• GronefeldGCLilienthalJKuckKHHohnloserSHImpact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized studyEur Heart J200324151430143612909072
   PubMed Web of Science ®Google Scholar
• CarlssonJMiketicSWindelerJRandomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) studyJ Am Coll Cardiol200341101690169612767648
   PubMed Web of Science ®Google Scholar
• van GelderIHagensVEBoskerHAA comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillationN Engl J Med2002347231834184012466507
   PubMed Web of Science ®Google Scholar
• RoyDTalajicMNattelSRhythm control versus rate control for atrial fibrillation and heart failureN Engl J Med2008358252667267718565859
   PubMed Web of Science ®Google Scholar
• MarshallDALevyARVidailletHCost-effectiveness of rhythm versus rate control in atrial fibrillationAnn Intern Med2004141965366115520421
   PubMed Web of Science ®Google Scholar
• CorleySDEpsteinAEDiMarcoJPRelationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) StudyCirculation2004109121509151315007003
   PubMed Web of Science ®Google Scholar
• FreemanJVZhuRPOwensDKCost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillationAnn Intern Med2011154111121041570
   PubMed Web of Science ®Google Scholar
• ShahSVGageBFCost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillationCirculation2011123222562257021606397
   PubMed Web of Science ®Google Scholar
• KamelHJohnstonSCEastonJDKimASCost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attackStroke201243388188322308255
   PubMed Web of Science ®Google Scholar
• PinkJLaneSPirmohamedMHughesDADabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analysesBMJ2011343d633322042753
   PubMed Web of Science ®Google Scholar
• HohnloserSHCrijnsHJvan EickelsMEffect of dronedarone on cardiovascular events in atrial fibrillationN Engl J Med2009360766867819213680
   PubMed Web of Science ®Google Scholar
• NaccarelliGVJohnstonSSLinJPatelPPSchulmanKLCost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United StatesClin Cardiol201033527027920513065
   PubMed Web of Science ®Google Scholar
• EhrlichJRNattelSAtrial-selective pharmacological therapy for atrial fibrillation: hype or hope?Curr Opin Cardiol2009241505519077816
   PubMed Web of Science ®Google Scholar
• BajpaiASavelievaICammAJTreatment of atrial fibrillationBr Med Bull2008881759419059992
   PubMed Web of Science ®Google Scholar
• sanofi-aventisMultaq [package insert]Bridgewater, NJsanofi-aventis US LLC2012
   Google Scholar
• ConnollySJCrijnsHJTorp-PedersenCAnalysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutterCirculation20091201174118019752319
   PubMed Web of Science ®Google Scholar
• DavyJMHeroldMHoglundCDronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation (ERATO) studyAm Heart J2008156352752918760136
   PubMed Web of Science ®Google Scholar
• SinghBNConnollySJCrijnsHJDronedarone for maintenance of sinus rhythm in atrial fibrillation or flutterN Engl J Med20073571098799917804843
   PubMed Web of Science ®Google Scholar
• TouboulPBrugadaJCapucciACrijnsHJEdvardssonNHohnloserSHDronedarone for prevention of atrial fibrillation: a dose-ranging studyEur Heart J200324161481148712919771
   PubMed Web of Science ®Google Scholar
• KoberLTorp-PedersenCMcMurrayJJIncreased mortality after dronedarone therapy for severe heart failureN Engl J Med2008358252678268718565860
   PubMed Web of Science ®Google Scholar
• ConnollySJCammAJHalperinJLDronedarone in high-risk permanent atrial fibrillationN Engl J Med2011365242268227622082198
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA Drug Safety Communication: Severe liver injury associated with the use of dronedarone (marketed as Multaq)January 142011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htmAccessed July 13, 2011
   Google Scholar
• US Food and Drug AdministrationPotential signals of serious risks/new safety information identified by the adverse event reporting system (AERS) between July–September 2010January 112011 Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm237585.htmAccessed March 21, 2011
   Google Scholar
• QuarterWatchQuarterWatch: 2010 Quarter 1. Monitoring MedWatch ReportsSignals for acetaminophen, dronedarone and botulinum toxin products [executive summary]November 42010 Available from: http://freepdfhosting.com/078147c86d.pdfAccessed March 21, 2011
   Google Scholar
• US Food and Drug AdministrationFDA Drug Safety Communication: review update of multaq (dronedarone) and increased risk of death and serious cardiovascular adverse eventsDecember 212011 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm283933.htmAccessed January 3, 2012
   Google Scholar
• MerckMerck to Acquire Rights to Vernakalant i.v. in Canada, Mexico and the United States from AstellasJul 262011 Available from: http://www.merck.com/newsroom/news-release-archive/research-and-development/2011_0726.htmlAccessed November 1, 2011
   Google Scholar
• CammAJCapucciAHohnloserSHA randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillationJ Am Coll Cardiol201157331332121232669
   PubMed Web of Science ®Google Scholar
• ChengJWVernakalant in the management of atrial fibrillationAnn Pharmacother200842453354218334607
   PubMed Web of Science ®Google Scholar
• EhrlichJRNattelSNovel approaches for pharmacological management of atrial fibrillationDrugs200969775777419441867
   PubMed Web of Science ®Google Scholar
• NaultIMiyazakiSForclazADrugs vs ablation for the treatment of atrial fibrillation: the evidence supporting catheter ablationEur Heart J20103191046105420332181
   PubMed Web of Science ®Google Scholar
• CappatoRCalkinsHChenSAWorldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillationCirculation200511191100110515723973
   PubMed Web of Science ®Google Scholar
• ChanPSVijanSMoradyFOralHCost-effectiveness of radio frequency catheter ablation for atrial fibrillationJ Am Coll Cardiol200647122513252016781382
   PubMed Web of Science ®Google Scholar
• ReynoldsMRZimetbaumPJosephsonMEEllisEDanilovTCohenDJCost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillationCirc Arrhythm Electrophysiol20092436236919808491
   PubMed Web of Science ®Google Scholar
• RodgersMMcKennaCPalmerSCurative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluationHealth Technol Assess20081234iiixiii1
   Web of Science ®Google Scholar